Growth • Prothena Corp
PRTA
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
178%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
0%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
0%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!